Will fund programme for another 12 months while divesting ongoing activities to Momenta
Generally competent at strategic planning, how can pharma transition from acceptable to exceptional to deliver gold standard performances?
How UK biopharma must adapt to a changing landscape
Launches global competition inviting submissions via Facebook
She becomes clinical project director at the French biotech
Big data, the cloud and the value of insights
Dr Sven Zimmerman and Mylène Fleurant join the Swiss biotech
Hopes the Moodivator app will complement treatment and support care teams
Can you measure return on investment (ROI) from compliant, patient-centred skills training for key opinion leaders?